The Implications of Positive Peritoneal Lavage Cytology in Potentially Resectable Pancreatic Cancer
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
The clinical implications of peritoneal lavage cytology (CY) status in patients with potentially resectable pancreatic cancer have not been established.
We retrospectively reviewed clinical data from 254 consecutive patients who underwent macroscopically curative resection for pancreatic cancer from February 2003 to December 2010 in our institution. Correlations between CY status and survival and clinicopathological findings were investigated.
Of the 254 patients, 20 were CY+ (7.9 %). There were no significant differences between CY+ and CY− patients in background data (age, sex, the level of preoperative tumor marker, and adjuvant chemotherapy). Patients with positive serosal invasion were more likely to be CY+ than those with negative serosal invasion (P < 0.001) by univariate analysis. The median overall survival of CY+ patients and CY− patients was 23.8 months (95 % CI = 17.6–29.8) and 26.5 months (95 % CI = 20.7–32.3), respectively (P = 0.302). The median recurrence-free survival of CY+ and CY− patients was 8.1 months (95 % CI = 0.0–17.9) and 13.5 months (95 % CI = 11.5–15.5), respectively (P = 0.089).
CY+ status without other distant metastasis does not necessarily preclude resection in patients with pancreatic cancer.
- Siegel R, Ward E, Brawley O, Jemal A (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61:212–236 CrossRef
- Gillen S, Schuster T, Meyer Zum Buschenfelde C et al (2010) Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 7:e1000267 CrossRef
- Aletti GD, Gallenberg MM, Cliby WA et al (2007) Current management strategies for ovarian cancer. Mayo Clin Proc 82:751–770
- Japanese Gastric Cancer Association (2011) Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer 14:101–112 CrossRef
- American Joint Committee on Cancer (2010) Exocrine and endocrine pancreas. In: The AJCC Cancer Staging Manual, 7th ed. Springer, New York, pp 241–249
- Clark CJ, Traverso LW (2010) Positive peritoneal lavage cytology is a predictor of worse survival in locally advanced pancreatic cancer. Am J Surg 199:657–662 CrossRef
- Fernandez-del Castillo C, Rattner DW, Warshaw AL (1995) Further experience with laparoscopy and peritoneal cytology in the staging of pancreatic cancer. Br J Surg 82:1127–1129 CrossRef
- Jimenez RE, Warshaw AL, Fernandez-Del Castillo C (2000) Laparoscopy and peritoneal cytology in the staging of pancreatic cancer. J Hepatobiliary Pancreat Surg 7:15–20 CrossRef
- Leach SD, Rose JA, Lowy AM et al (1995) Significance of peritoneal cytology in patients with potentially resectable adenocarcinoma of the pancreatic head. Surgery 118:472–478 CrossRef
- Makary MA, Warshaw AL, Centeno BA et al (1998) Implications of peritoneal cytology for pancreatic cancer management. Arch Surg 133:361–365 CrossRef
- Merchant NB, Conlon KC, Saigo P et al (1999) Positive peritoneal cytology predicts unresectability of pancreatic adenocarcinoma. J Am Coll Surg 188:421–426 CrossRef
- Meszoely IM, Lee JS, Watson JC et al (2004) Peritoneal cytology in patients with potentially resectable adenocarcinoma of the pancreas. Am Surg 70:208–213 discussion 213–204
- Nakao A, Fujii T, Sugimoto H et al (2006) Oncological problems in pancreatic cancer surgery. World J Gastroenterol 12:4466–4472
- Warshaw AL (1991) Implications of peritoneal cytology for staging of early pancreatic cancer. Am J Surg 161:26–29 discussion 29–30 CrossRef
- Yachida S, Fukushima N, Sakamoto M et al (2002) Implications of peritoneal washing cytology in patients with potentially resectable pancreatic cancer. Br J Surg 89:573–578 CrossRef
- Yamada S, Takeda S, Fujii T et al (2007) Clinical implications of peritoneal cytology in potentially resectable pancreatic cancer: positive peritoneal cytology may not confer an adverse prognosis. Ann Surg 246:254–258 CrossRef
- Ueno H, Kosuge T, Matsuyama Y et al (2009) A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer 101:908–915 CrossRef
- Tempero MA, Arnoletti JP, Behrman S et al (2010) Pancreatic adenocarcinoma. J Natl Compr Cancer Netw 8:972–1017
- Ferrone CR, Haas B, Tang L et al (2006) The influence of positive peritoneal cytology on survival in patients with pancreatic adenocarcinoma. J Gastrointest Surg 10:1347–1353 CrossRef
- Conroy T, Desseigne F, Ychou M et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817–1825 CrossRef
- Katz MH, Pisters PW, Evans DB et al (2008) Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg 206:833–846 discussion 846–838 CrossRef
- The Implications of Positive Peritoneal Lavage Cytology in Potentially Resectable Pancreatic Cancer
World Journal of Surgery
Volume 36, Issue 9 , pp 2187-2191
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Department of Gastroenterological Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan
- 2. Department of Hepato-Biliary-Pancreatic Surgery, National Defense Medical College Hospital, Tokorozawa, Japan